
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc is positioned to advance its clinical-stage pipeline with promising candidates such as prulacabtagene leucel (prula-cel) for autoimmune diseases and the next-generation ADI-212 for oncology. The preliminary Phase 1 data for prula-cel indicate meaningful efficacy in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE), suggesting a strong therapeutic profile that differentiates it from competitors. Additionally, the company’s strategy to utilize third-party manufacturers for commercial-scale production is expected to mitigate manufacturing risks, enhancing the outlook for future growth driven by additional autoimmune indications and oncology opportunities.
Bears say
Adicet Bio is facing significant financial risks that contribute to a negative outlook on its stock. The company projects a notable net loss of $11.58 per share by 2026, alongside increased uncertainty regarding the likelihood of success for its key product candidates, as evidenced by a reduced probability of success for ADI-001 in treating Lupus Nephritis and Systemic Lupus Erythematosus, which has dropped to 15%. Additionally, the potential for adverse clinical data, slower development timelines, and the lack of FDA approval for gamma-delta T-cell therapies amplify concerns about the company's market position and long-term revenue generation.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares